New and Emerging Therapies for Pediatric Atopic Dermatitis
Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by pruritus, inflammatory erythematous skin lesions, and skin-barrier defect. Current mainstay treatments of emollients, steroids, calcineurin inhibitors, and immunosuppressants have limited efficacy and potentially serious...
Gespeichert in:
| Veröffentlicht in: | Paediatric drugs 2019-08, Vol.21 (4), p.239-260 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 260 |
|---|---|
| container_issue | 4 |
| container_start_page | 239 |
| container_title | Paediatric drugs |
| container_volume | 21 |
| creator | Nguyen, Henry L. Anderson, Katelyn R. Tollefson, Megha M. |
| description | Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by pruritus, inflammatory erythematous skin lesions, and skin-barrier defect. Current mainstay treatments of emollients, steroids, calcineurin inhibitors, and immunosuppressants have limited efficacy and potentially serious side effects. Recent advances and understanding of the pathogenesis of AD have resulted in new therapies that target specific pathways with increased efficacy and the potential for less systemic side effects. New FDA-approved therapies for AD are crisaborole and dupilumab. The JAK-STAT inhibitors (baricitinib, upadacitinib, PF-04965842, ASN002, tofacitinib, ruxolitinib, and delgocitinib) have the most promising results of the emerging therapies. Other drugs with potential include the aryl hydrocarbon receptor modulating agent tapinarof, the IL-4/IL-13 antagonists lebrikizumab and tralokinumab, and the IL-31Rα antagonist nemolizumab. In this review, new and emerging AD therapies will be discussed along with their mechanisms of action and their potential based on clinical study data. |
| doi_str_mv | 10.1007/s40272-019-00342-w |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2399201067</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A714588370</galeid><sourcerecordid>A714588370</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-ebad6abdf20f1d30e8b9ce34efcd235db619d94907c5ce3fa6fb072e48cbb72b3</originalsourceid><addsrcrecordid>eNp9UctKAzEUDaLYWv0BFzLgempency4K7U-QNRFXYc8bmqKM1OTKcW_N7ZVEUSyuOHcc-7rIHRK8JBgLC4ix1TQHJMqx5hxmq_3UJ8QUeU0YfubP89HpSh76CjGBcZEsIIeoh4jrEhi1keXD7DOVGOzaQ1h7pt5NnuBoJYeYubakD2B9aoL3mTjrl2mcAWhVp3vfDxGB069RjjZxQF6vp7OJrf5_ePN3WR8nxvOaZeDVrZQ2jqKHbEMQ6krA4yDM5aykdUFqWzFKyzMKOFOFU5jQYGXRmtBNRug823dZWjfVhA7uWhXoUktJWVVlXbFhfhhzdUrSN-4tgvK1D4aORaEj8qSCZxYwz9Y6VmovWkbcD7hvwR0KzChjTGAk8vgaxXeJcHy0wW5dUGmi8uNC3KdRGe7iVe6Bvst-Tp7IrAtIaZUM4fws9I_ZT8AdNqRSA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2399201067</pqid></control><display><type>article</type><title>New and Emerging Therapies for Pediatric Atopic Dermatitis</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Nguyen, Henry L. ; Anderson, Katelyn R. ; Tollefson, Megha M.</creator><creatorcontrib>Nguyen, Henry L. ; Anderson, Katelyn R. ; Tollefson, Megha M.</creatorcontrib><description>Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by pruritus, inflammatory erythematous skin lesions, and skin-barrier defect. Current mainstay treatments of emollients, steroids, calcineurin inhibitors, and immunosuppressants have limited efficacy and potentially serious side effects. Recent advances and understanding of the pathogenesis of AD have resulted in new therapies that target specific pathways with increased efficacy and the potential for less systemic side effects. New FDA-approved therapies for AD are crisaborole and dupilumab. The JAK-STAT inhibitors (baricitinib, upadacitinib, PF-04965842, ASN002, tofacitinib, ruxolitinib, and delgocitinib) have the most promising results of the emerging therapies. Other drugs with potential include the aryl hydrocarbon receptor modulating agent tapinarof, the IL-4/IL-13 antagonists lebrikizumab and tralokinumab, and the IL-31Rα antagonist nemolizumab. In this review, new and emerging AD therapies will be discussed along with their mechanisms of action and their potential based on clinical study data.</description><identifier>ISSN: 1174-5878</identifier><identifier>EISSN: 1179-2019</identifier><identifier>DOI: 10.1007/s40272-019-00342-w</identifier><identifier>PMID: 31364023</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Atopic dermatitis ; Child ; Children ; Clinical trials ; Cytokines ; Dermatitis ; Dermatitis, Atopic - drug therapy ; Dermatitis, Atopic - pathology ; Dermatologic agents ; Dermatology ; Diseases ; Drug therapy ; Eczema ; FDA approval ; Formulae, receipts, prescriptions ; Humans ; Immune system ; Internal Medicine ; Leading Article ; Licensing, certification and accreditation ; Light therapy ; Lymphoma ; Medicine ; Medicine & Public Health ; Monoclonal antibodies ; Pathogenesis ; Pediatric research ; Pediatrics ; Pharmacotherapy ; Pruritus ; Signal transduction ; Skin ; Skin diseases</subject><ispartof>Paediatric drugs, 2019-08, Vol.21 (4), p.239-260</ispartof><rights>Springer Nature Switzerland AG 2019</rights><rights>COPYRIGHT 2019 Springer</rights><rights>Copyright Springer Nature B.V. Aug 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-ebad6abdf20f1d30e8b9ce34efcd235db619d94907c5ce3fa6fb072e48cbb72b3</citedby><cites>FETCH-LOGICAL-c442t-ebad6abdf20f1d30e8b9ce34efcd235db619d94907c5ce3fa6fb072e48cbb72b3</cites><orcidid>0000-0002-5051-4718</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40272-019-00342-w$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40272-019-00342-w$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31364023$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nguyen, Henry L.</creatorcontrib><creatorcontrib>Anderson, Katelyn R.</creatorcontrib><creatorcontrib>Tollefson, Megha M.</creatorcontrib><title>New and Emerging Therapies for Pediatric Atopic Dermatitis</title><title>Paediatric drugs</title><addtitle>Pediatr Drugs</addtitle><addtitle>Paediatr Drugs</addtitle><description>Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by pruritus, inflammatory erythematous skin lesions, and skin-barrier defect. Current mainstay treatments of emollients, steroids, calcineurin inhibitors, and immunosuppressants have limited efficacy and potentially serious side effects. Recent advances and understanding of the pathogenesis of AD have resulted in new therapies that target specific pathways with increased efficacy and the potential for less systemic side effects. New FDA-approved therapies for AD are crisaborole and dupilumab. The JAK-STAT inhibitors (baricitinib, upadacitinib, PF-04965842, ASN002, tofacitinib, ruxolitinib, and delgocitinib) have the most promising results of the emerging therapies. Other drugs with potential include the aryl hydrocarbon receptor modulating agent tapinarof, the IL-4/IL-13 antagonists lebrikizumab and tralokinumab, and the IL-31Rα antagonist nemolizumab. In this review, new and emerging AD therapies will be discussed along with their mechanisms of action and their potential based on clinical study data.</description><subject>Atopic dermatitis</subject><subject>Child</subject><subject>Children</subject><subject>Clinical trials</subject><subject>Cytokines</subject><subject>Dermatitis</subject><subject>Dermatitis, Atopic - drug therapy</subject><subject>Dermatitis, Atopic - pathology</subject><subject>Dermatologic agents</subject><subject>Dermatology</subject><subject>Diseases</subject><subject>Drug therapy</subject><subject>Eczema</subject><subject>FDA approval</subject><subject>Formulae, receipts, prescriptions</subject><subject>Humans</subject><subject>Immune system</subject><subject>Internal Medicine</subject><subject>Leading Article</subject><subject>Licensing, certification and accreditation</subject><subject>Light therapy</subject><subject>Lymphoma</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Monoclonal antibodies</subject><subject>Pathogenesis</subject><subject>Pediatric research</subject><subject>Pediatrics</subject><subject>Pharmacotherapy</subject><subject>Pruritus</subject><subject>Signal transduction</subject><subject>Skin</subject><subject>Skin diseases</subject><issn>1174-5878</issn><issn>1179-2019</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9UctKAzEUDaLYWv0BFzLgempency4K7U-QNRFXYc8bmqKM1OTKcW_N7ZVEUSyuOHcc-7rIHRK8JBgLC4ix1TQHJMqx5hxmq_3UJ8QUeU0YfubP89HpSh76CjGBcZEsIIeoh4jrEhi1keXD7DOVGOzaQ1h7pt5NnuBoJYeYubakD2B9aoL3mTjrl2mcAWhVp3vfDxGB069RjjZxQF6vp7OJrf5_ePN3WR8nxvOaZeDVrZQ2jqKHbEMQ6krA4yDM5aykdUFqWzFKyzMKOFOFU5jQYGXRmtBNRug823dZWjfVhA7uWhXoUktJWVVlXbFhfhhzdUrSN-4tgvK1D4aORaEj8qSCZxYwz9Y6VmovWkbcD7hvwR0KzChjTGAk8vgaxXeJcHy0wW5dUGmi8uNC3KdRGe7iVe6Bvst-Tp7IrAtIaZUM4fws9I_ZT8AdNqRSA</recordid><startdate>20190801</startdate><enddate>20190801</enddate><creator>Nguyen, Henry L.</creator><creator>Anderson, Katelyn R.</creator><creator>Tollefson, Megha M.</creator><general>Springer International Publishing</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><orcidid>https://orcid.org/0000-0002-5051-4718</orcidid></search><sort><creationdate>20190801</creationdate><title>New and Emerging Therapies for Pediatric Atopic Dermatitis</title><author>Nguyen, Henry L. ; Anderson, Katelyn R. ; Tollefson, Megha M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-ebad6abdf20f1d30e8b9ce34efcd235db619d94907c5ce3fa6fb072e48cbb72b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Atopic dermatitis</topic><topic>Child</topic><topic>Children</topic><topic>Clinical trials</topic><topic>Cytokines</topic><topic>Dermatitis</topic><topic>Dermatitis, Atopic - drug therapy</topic><topic>Dermatitis, Atopic - pathology</topic><topic>Dermatologic agents</topic><topic>Dermatology</topic><topic>Diseases</topic><topic>Drug therapy</topic><topic>Eczema</topic><topic>FDA approval</topic><topic>Formulae, receipts, prescriptions</topic><topic>Humans</topic><topic>Immune system</topic><topic>Internal Medicine</topic><topic>Leading Article</topic><topic>Licensing, certification and accreditation</topic><topic>Light therapy</topic><topic>Lymphoma</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Monoclonal antibodies</topic><topic>Pathogenesis</topic><topic>Pediatric research</topic><topic>Pediatrics</topic><topic>Pharmacotherapy</topic><topic>Pruritus</topic><topic>Signal transduction</topic><topic>Skin</topic><topic>Skin diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nguyen, Henry L.</creatorcontrib><creatorcontrib>Anderson, Katelyn R.</creatorcontrib><creatorcontrib>Tollefson, Megha M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Paediatric drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nguyen, Henry L.</au><au>Anderson, Katelyn R.</au><au>Tollefson, Megha M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New and Emerging Therapies for Pediatric Atopic Dermatitis</atitle><jtitle>Paediatric drugs</jtitle><stitle>Pediatr Drugs</stitle><addtitle>Paediatr Drugs</addtitle><date>2019-08-01</date><risdate>2019</risdate><volume>21</volume><issue>4</issue><spage>239</spage><epage>260</epage><pages>239-260</pages><issn>1174-5878</issn><eissn>1179-2019</eissn><abstract>Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by pruritus, inflammatory erythematous skin lesions, and skin-barrier defect. Current mainstay treatments of emollients, steroids, calcineurin inhibitors, and immunosuppressants have limited efficacy and potentially serious side effects. Recent advances and understanding of the pathogenesis of AD have resulted in new therapies that target specific pathways with increased efficacy and the potential for less systemic side effects. New FDA-approved therapies for AD are crisaborole and dupilumab. The JAK-STAT inhibitors (baricitinib, upadacitinib, PF-04965842, ASN002, tofacitinib, ruxolitinib, and delgocitinib) have the most promising results of the emerging therapies. Other drugs with potential include the aryl hydrocarbon receptor modulating agent tapinarof, the IL-4/IL-13 antagonists lebrikizumab and tralokinumab, and the IL-31Rα antagonist nemolizumab. In this review, new and emerging AD therapies will be discussed along with their mechanisms of action and their potential based on clinical study data.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>31364023</pmid><doi>10.1007/s40272-019-00342-w</doi><tpages>22</tpages><orcidid>https://orcid.org/0000-0002-5051-4718</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1174-5878 |
| ispartof | Paediatric drugs, 2019-08, Vol.21 (4), p.239-260 |
| issn | 1174-5878 1179-2019 |
| language | eng |
| recordid | cdi_proquest_journals_2399201067 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Atopic dermatitis Child Children Clinical trials Cytokines Dermatitis Dermatitis, Atopic - drug therapy Dermatitis, Atopic - pathology Dermatologic agents Dermatology Diseases Drug therapy Eczema FDA approval Formulae, receipts, prescriptions Humans Immune system Internal Medicine Leading Article Licensing, certification and accreditation Light therapy Lymphoma Medicine Medicine & Public Health Monoclonal antibodies Pathogenesis Pediatric research Pediatrics Pharmacotherapy Pruritus Signal transduction Skin Skin diseases |
| title | New and Emerging Therapies for Pediatric Atopic Dermatitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T04%3A21%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20and%20Emerging%20Therapies%20for%20Pediatric%20Atopic%20Dermatitis&rft.jtitle=Paediatric%20drugs&rft.au=Nguyen,%20Henry%20L.&rft.date=2019-08-01&rft.volume=21&rft.issue=4&rft.spage=239&rft.epage=260&rft.pages=239-260&rft.issn=1174-5878&rft.eissn=1179-2019&rft_id=info:doi/10.1007/s40272-019-00342-w&rft_dat=%3Cgale_proqu%3EA714588370%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2399201067&rft_id=info:pmid/31364023&rft_galeid=A714588370&rfr_iscdi=true |